Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.

摘要: Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many advance-stage epithelial cancers. These agents have superior ability to target cancers cells and better safety profile compared conventional chemotherapies. However, cutaneous adverse events common due interference of epidermal receptor (EGFR) signaling in skin. Cutaneous toxicities lead poor compliance, drug cessation, psychosocial discomfort. This paper summarizes current knowledge concerning presentation management skin toxicity from EGFRI. The dermatologic papulopustules xerosis. Less findings paronychia, regulatory abnormalities hair growth, maculopapular rash, mucositis, postinflammatory hyperpigmentation. Radiation enhances EGFRI rash synergistic toxicity. There is a positive correlation between occurrence severity effects tumor response. To date, prophylactic systemic tetracycline class antibiotics proven be most effective regime.